Sign In
Buy ALLR
$1.58
-0.110 (-6.51%)
At Close: Jun 03, 2026
Reinhausen Manufacturing Inc Celebrates Ribbon Cutting for Plant Expansion in Humboldt
06:22pm, Tuesday, 23'rd Jul 2024
HUMBOLDT, Tenn.--(BUSINESS WIRE)--Reinhausen Manufacturing Inc. (RM), a subsidiary of Germany-based Maschinenfabrik Reinhausen, is thrilled to announce the official ribbon cutting of its newly expande
Allarity Therapeutics Outlines Company's 2024 Progress and Objectives
06:30am, Monday, 22'nd Jul 2024
Current Cash Balance of $20 million Expected to Provide Runway Into 2026 Allarity to Pause Use of ATM Cap Table Successfully Cleaned Up Allarity's Stenoparib Shows Extended Duration of Phase 2 Clinica
Allarity Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
08:00am, Monday, 20'th May 2024
Boston (May 20, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer tr
- Phase 2 Trial of Stenoparib Concluded Early due to Clear Clinical Benefits Achieved - On Track to Regain Compliance with All Nasdaq Listing Requirements - No Variable Priced Securities are Outstandi
All You Need to Know About Allarity Therapeutics, Inc. (ALLR) Rating Upgrade to Buy
01:01pm, Tuesday, 07'th May 2024
Allarity Therapeutics, Inc. (ALLR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common Stock
09:30am, Tuesday, 07'th May 2024
- Conversions Eliminate All Variable Priced Derivative Securities - Conversions Eliminate Any Market Overhang from Warrants - Series A Preferred and Warrant Conversions were Investor Initiated - Limit
Allarity Therapeutics Exceeds Nasdaq's Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1
08:00am, Monday, 06'th May 2024
- Stockholders' equity significantly surpasses the $2.5 million minimum required by Nasdaq
Why Is Allarity Therapeutics (ALLR) Stock Up 39% Today?
10:46am, Thursday, 02'nd May 2024
Allarity Therapeutics (NASDAQ: ALLR ) stock is rocketing higher on Thursday after the clinical-stage biopharmaceutical company shared results from a Phase 2 clinical trial. Allarity Therapeutics annou
Boston (May 2, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments,
Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement
07:00am, Monday, 29'th Apr 2024
Boston (April 29, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatm
Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)
09:10am, Wednesday, 17'th Apr 2024
Boston (April 17, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatmen
Why Is Allarity Therapeutics (ALLR) Stock Up 41% Today?
08:18am, Friday, 12'th Apr 2024
Allarity Therapeutics (NASDAQ: ALLR ) stock is heading higher on Friday alongside heavy pre-market trading. Investors will note that this movement comes after the company announced a prospectus suppl
Allarity Therapeutics Announces 1-for-20 Reverse Stock Split
09:15am, Thursday, 04'th Apr 2024
Boston (April 4, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatme
The stenoparib Phase 2 monotherapy trial in advanced, recurrent ovarian cancer continues to show promise, prompting shift in resources to accelerate stenoparib development Further development of IXEMP
Boston (March 25, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatm
